The Early to Middle Ordovician graptolite faunal succession of the Trail Creek region, central Idaho, U.S.A

The Middle Ordovician graptolite biostratigraphy of the Trail Creek region of Idaho is reviewed and revised. The oldest known fauna belongs to the Didymograptellus bifidus Biozone. The Isograptus victoriae lunatus, I. victoriae maximodivergens, Oncograptus, Undulograptus austrodentatus and Holmograptus lentus Biozones can be differentiated. Pseudophyllograptus archaios (Braithwaite) is found for the first time in the Trail Creek region. This species represents a conspicuous North American mid-continent faunal element and enables the correlation of the endemic P. archaios-C. flexilis Biozone of Utah with the D. bifidus Biozone of the Pacific faunal realm, thus, providing an important tool for the correlation of endemic mid-continent faunas with the pandemic deep water graptolite faunas

A weak-coupling superconductivity in the electron doped NaFe0.95_{0.95}Co0.05_{0.05}As is revealed by ARPES

We report a systematic study on the electronic structure and superconducting (SC) gaps in electron doped NaFe$_{0.95}$Co$_{0.05}$As superconductor using angle-resolved photoemission spectroscopy. Hole-like Fermi sheets are at the zone center and electron-like Fermi sheets are at the zone corner, and are mainly contributed by $xz$ and $yz$ orbital characters. Our results reveal a $\frac{\Delta}{K_B T_c}$ in the range of 1.8-2.1, suggesting a weak-coupling superconductivity in these compounds. Gap closing above the transition temperature ($T_c$) shows the absence of pseudogaps. Gap evolution with temperature follow the BCS gap equation near the $\Gamma$, $Z$, and $M$ high symmetry points. Furthermore, an almost isotropic superconductivity along $k_z$ direction in the momentum space is observed by varying the excitation energies.Comment: 6 pages, 5 figures, Accepted by Phy.Rev.

Marketing e empreendedorismo: uma relação umbilical

Este relatório, ao constatar a diferente aplicabilidade dos conhecimentos e utensílios de marketing, devido às empresas maduras e de maior dimensão desfrutarem de recursos que os empreendedores e gestores de pequenas empresas não possuem, tem como objetivo, baseado na experiencia profissional do autor e respetivo enquadramento teórico e científico, caracterizar a relação entre o marketing e o empreendedorismo, permitindo uma melhor compreensão das alternativas existentes para os empreendedores e gestores de pequenas empresas, além de uma identificação dos seus comportamentos e atitudes mais recorrentes. Neste contexto, ganha preponderância uma reflexão sobre o marketing empreendedor, como ocorre e em que circunstâncias pode auxiliar o empreendedor a tomar decisões e simultaneamente não perder competitividade para os seus potenciais concorrentes. Assim, a comunicação boca-a-boca, o círculo de influências do empreendedor e as redes sociais inovadoras, são cada vez mais consideradas e reconhecidas como garante de competitividade e inovação, num ambiente empresarial em constante mudança; ABSTRACT: This report, observes the different applicability of the knowledge and marketing tools, justified by the existence of bigger possessions that mature companies have, comparing to the resources that the entrepreneurs and managers of small companies do not own. This report, based in the professional experience of the author and theoretical and scientific knowledge, aims to characterize the connection between marketing and the entrepreneurship, allowing a better understanding of the alternatives and behaviors that entrepreneurs and managers of small companies could take, in order to compete with their rivals. In this context, it gains prominence a reflection on the entrepreneurial marketing, when it occurs and which circumstances can assist the entrepreneur to take decisions in order to not lose competitiveness for its potential opponents. Thus, the buzz communication, the circle of influences of the entrepreneur and the new social networks, are each time more considered and recognized as it guarantees of competitiveness and innovation, in an enterprise environment constantly in change

An academic challenge to the entrepreneurial university: the spatial power of the ‘Slow Swimming Club’

© 2018 Society for Research into Higher Education. The entrepreneurial university is a vague notion that has evolved by applying the concepts of enterprise and entrepreneurship to a university context. The blurring of enterprise with entrepreneurship has allowed the entrepreneurial university to be increasingly underpinned by a managerialist discourse, typified by functionalisation and marketisation; culminating in academic disempowerment, dissatisfaction and subsequent disengagement. In response to such dissatisfaction, this paper reflects on a playful space, called the Slow Swimming Club (SSC), produced by several academics. The research takes a collective auto-ethnographic approach and employs Foucault’s heterotopology, as a conceptual frame, to understand the collective impact of this SSC entrepreneuring space. We relate the disconnection of the SSC to the process of critically connecting academics, back to their universities and consider whether such academic resistance, rooted in play, corporeal sensibility and emancipation, has the potential to enact social change and enhance entrepreneurial potential

Acute childhood diarrhoea in northern Ghana: epidemiological, clinical and microbiological characteristics

<p>Abstract</p> <p>Background</p> <p>Acute diarrhoea is a major cause of childhood morbidity and mortality in sub-Saharan Africa. Its microbiological causes and clinico-epidemiological aspects were examined during the dry season 2005/6 in Tamale, urban northern Ghana.</p> <p>Methods</p> <p>Stool specimens of 243 children with acute diarrhoea and of 124 control children were collected. Patients were clinically examined, and malaria and anaemia were assessed. Rota-, astro-, noro- and adenoviruses were identified by (RT-) PCR assays. Intestinal parasites were diagnosed by microscopy, stool antigen assays and PCR, and bacteria by culturing methods.</p> <p>Results</p> <p>Watery stools, fever, weakness, and sunken eyes were the most common symptoms in patients (mean age, 10 months). Malaria occurred in 15% and anaemia in 91%; underweight (22%) and wasting (19%) were frequent. Intestinal micro-organisms were isolated from 77% of patients and 53% of controls (<it>P </it>< 0.0001). The most common pathogens in patients were rotavirus (55%), adenovirus (28%) and norovirus (10%); intestinal parasites (5%) and bacteria (5%) were rare. Rotavirus was the only pathogen found significantly more frequently in patients than in controls (odds ratio 7.7; 95%CI, 4.2–14.2), and was associated with young age, fever and watery stools. Patients without an identified cause of diarrhoea more frequently had symptomatic malaria (25%) than those with diagnosed intestinal pathogens (12%, <it>P </it>= 0.02).</p> <p>Conclusion</p> <p>Rotavirus-infection is the predominant cause of acute childhood diarrhoea in urban northern Ghana. The abundance of putative enteropathogens among controls may indicate prolonged excretion or limited pathogenicity. In this population with a high burden of diarrhoeal and other diseases, sanitation, health education, and rotavirus-vaccination can be expected to have substantial impact on childhood morbidity.</p

A unified approach to molecular epidemiology investigations: tools and patterns in California as a case study for endemic shigellosis

<p>Abstract</p> <p>Background</p> <p>Shigellosis causes diarrheal disease in humans from both developed and developing countries, and multi-drug resistance is an emerging problem. The objective of this study is to present a unified approach that can be used to characterize endemic and outbreak patterns of shigellosis using use a suite of epidemiologic and molecular techniques. The approach is applied to a California case study example of endemic shigellosis at the population level.</p> <p>Methods</p> <p>Epidemiologic patterns were evaluated with respect to demographics, multi-drug resistance, antimicrobial resistance genes, plasmid profiles, and pulsed-field gel electrophoresis (PFGE) fingerprints for the 43 <it>Shigella </it>isolates obtained by the Monterey region health departments over the two year period from 2004-2005.</p> <p>Results</p> <p>The traditional epidemiologic as well as molecular epidemiologic findings were consistent with endemic as compared to outbreak shigellosis in this population. A steady low level of cases was observed throughout the study period and high diversity was observed among strains. In contrast to most studies in developed countries, the predominant species was <it>Shigella flexneri </it>(51%) followed closely by <it>S. sonnei </it>(49%). Over 95% of <it>Shigella </it>isolates were fully resistant to three or more antimicrobial drug subclasses, and 38% of isolates were resistant to five or more subclasses. More than half of <it>Shigella </it>strains tested carried the <it>tetB</it>, <it>catA</it>, or <it>bla</it>_TEMgenes for antimicrobial resistance to tetracycline, chloramphenicol, and ampicillin, respectively.</p> <p>Conclusion</p> <p>This study shows how epidemiologic patterns at the host and bacterial population levels can be used to investigate endemic as compared to outbreak patterns of shigellosis in a community. Information gathered as part of such investigations will be instrumental in identifying emerging antimicrobial resistance, for developing treatment guidelines appropriate for that community, and to provide baseline data with which to compare outbreak strains in the future.</p

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.